Siamenoside ICAS# 126105-12-2 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 126105-12-2 | SDF | Download SDF |
| PubChem ID | 71307460 | Appearance | White powder |
| Formula | C54H92O24 | M.Wt | 1125.29 |
| Type of Compound | Triterpenoids | Storage | Desiccate at -20°C |
| Solubility | Soluble in water | ||
| Chemical Name | (2R,3R,4S,5S,6R)-2-[[(2R,3S,4S,5R,6S)-3,4-dihydroxy-6-[(3R,6R)-2-hydroxy-6-[(3S,8S,9R,10R,11R,13R,14S,17R)-11-hydroxy-4,4,9,13,14-pentamethyl-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,3,7,8,10,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-methylheptan-3-yl]oxy-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]-6-(hydroxymethyl)oxane-3,4,5-triol | ||
| SMILES | CC(CCC(C(C)(C)O)OC1C(C(C(C(O1)COC2C(C(C(C(O2)CO)O)O)O)O)O)OC3C(C(C(C(O3)CO)O)O)O)C4CCC5(C4(CC(C6(C5CC=C7C6CCC(C7(C)C)OC8C(C(C(C(O8)CO)O)O)O)C)O)C)C | ||
| Standard InChIKey | XJIPREFALCDWRQ-UYQGGQRHSA-N | ||
| Standard InChI | InChI=1S/C54H92O24/c1-22(23-15-16-52(6)30-12-10-24-25(54(30,8)31(58)17-53(23,52)7)11-14-32(50(24,2)3)76-47-43(68)39(64)35(60)27(19-56)73-47)9-13-33(51(4,5)70)77-49-45(78-48-44(69)40(65)36(61)28(20-57)74-48)41(66)37(62)29(75-49)21-71-46-42(67)38(63)34(59)26(18-55)72-46/h10,22-23,25-49,55-70H,9,11-21H2,1-8H3/t22-,23-,25-,26-,27-,28-,29-,30+,31-,32+,33-,34-,35-,36-,37-,38+,39+,40+,41+,42-,43-,44-,45-,46-,47+,48+,49+,52+,53-,54+/m1/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Siamenoside I is one of the mogrosides that has several kinds of bioactivities, it exhibits maltase inhibitory effect with the IC50 value of 12 mM. |
| Targets | LDL |
| In vitro | Sweet elements of Siraitia grosvenori inhibit oxidative modification of low-density lipoprotein.[Pubmed: 12236315]J Atheroscler Thromb. 2002;9(2):114-20.This study examined the ability of sweet elements extracted from Siraitia grosvenori (SG) to inhibit the oxidation of LDL. |
| In vivo | Triterpene glycosides of Siraitia grosvenori inhibit rat intestinal maltase and suppress the rise in blood glucose level after a single oral administration of maltose in rats.[Pubmed: 15826043]J Agric Food Chem. 2005 Apr 20;53(8):2941-6.The effect of the crude extract from Siraitia grosvenori Swingle (SG-ex) on the postprandial rise in blood glucose level was investigated. |
Siamenoside I Dilution Calculator
Siamenoside I Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 0.8887 mL | 4.4433 mL | 8.8866 mL | 17.7732 mL | 22.2165 mL |
| 5 mM | 0.1777 mL | 0.8887 mL | 1.7773 mL | 3.5546 mL | 4.4433 mL |
| 10 mM | 0.0889 mL | 0.4443 mL | 0.8887 mL | 1.7773 mL | 2.2216 mL |
| 50 mM | 0.0178 mL | 0.0889 mL | 0.1777 mL | 0.3555 mL | 0.4443 mL |
| 100 mM | 0.0089 mL | 0.0444 mL | 0.0889 mL | 0.1777 mL | 0.2222 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Siamenoside I is one of the mogrosides that has several kinds of bioactivities.
In Vivo:In rat, the metabolic reactions of siamenoside I include deglycosylation, hydroxylation, dehydrogenation, deoxygenation, isomerization, and glycosylation. Siamenoside I and its metabolites are mainly distributed to the intestines, stomach, kidneys, and brain[1].
References:
[1]. Yang XR, et al. Metabolites of Siamenoside I and Their Distributions in Rats. Molecules. 2016 Jan 30;21(2):176.
- 11-Oxo-mogroside V
Catalog No.:BCN2509
CAS No.:126105-11-1
- Rubiyunnanin C
Catalog No.:BCN8045
CAS No.:1261030-04-9
- I-BET-762
Catalog No.:BCC4474
CAS No.:1260907-17-2
- 6-O-Methylcerevisterol
Catalog No.:BCN6139
CAS No.:126060-09-1
- Atractyloside A
Catalog No.:BCN5383
CAS No.:126054-77-1
- GSK 525768A
Catalog No.:BCC1603
CAS No.:1260530-25-3
- 3-O-beta-Allopyranosyl-(1->4)-beta-oleandropyranosyl-11-O-isobutyryl-12-O-acetyltenacigenin B
Catalog No.:BCN6765
CAS No.:1260252-18-3
- Birinapant (TL32711)
Catalog No.:BCC2250
CAS No.:1260251-31-7
- TCS 21311
Catalog No.:BCC2443
CAS No.:1260181-14-3
- 3-Oxo-21alpha-methoxy-24,25,26,27-tetranortirucall-7-ene-23(21)-lactone
Catalog No.:BCN7028
CAS No.:1260173-73-6
- TAK-438
Catalog No.:BCC1182
CAS No.:1260141-27-2
- 28-Deoxonimbolide
Catalog No.:BCN4717
CAS No.:126005-94-5
- GNF179
Catalog No.:BCC5175
CAS No.:1261114-01-5
- BAPTA-AM
Catalog No.:BCC5456
CAS No.:126150-97-8
- Icariside E5
Catalog No.:BCN6140
CAS No.:126176-79-2
- Spiranthol A
Catalog No.:BCN7893
CAS No.:126192-35-6
- LY2886721
Catalog No.:BCC3807
CAS No.:1262036-50-9
- Ginsenoside Rg4
Catalog No.:BCN2713
CAS No.:126223-28-7
- Agrimonolide 6-O-glucoside
Catalog No.:BCN6141
CAS No.:126223-29-8
- INCB3344
Catalog No.:BCC1648
CAS No.:1262238-11-8
- Uralsaponin C
Catalog No.:BCN7906
CAS No.:1262326-46-4
- 24-Hydroxy-licoricesaponin A3
Catalog No.:BCN7896
CAS No.:1262326-47-5
- Uralsaponin D
Catalog No.:BCN7895
CAS No.:1262489-44-0
- (2R,3S)-Dihydrodehydroconiferyl alcohol
Catalog No.:BCN7886
CAS No.:126253-41-6
Sweet elements of Siraitia grosvenori inhibit oxidative modification of low-density lipoprotein.[Pubmed:12236315]
J Atheroscler Thromb. 2002;9(2):114-20.
This study examined the ability of sweet elements extracted from Siraitia grosvenori (SG) to inhibit the oxidation of LDL. We monitored the formation of conjugated diene during copper-mediated LDL oxidation in the presence or absence of sweet elements of whole extract of SG (SG extract) or cucurbitane glycosides (CGs) purified from SG extract as sweet elements. CGs consist of Mogroside IV (Mog.IV), Mogroside V (Mog.V), 11-Oxo-mogroside V (11-Oxo-mog.V), and Siamenoside I (Sia.I). In addition, the effect of these elements on human umbilical vein endothelial cell (HUVEC)- mediated LDL oxidation was tested by measuring production of lipid peroxides. SG extract inhibited copper-mediated LDL oxidation in a dose-dependent fashion, but neither glucose nor erythritol suppressed the oxidation. Among CGs, 11-Oxo-mog.V significantly inhibited LDL oxidation, and prolongation of the lag time during LDL oxidation by 11-Oxo-mog.V was dose-dependent. The lag time (119.7 +/- 8.9 min) in the presence of 200 microM 11-Oxo-mog.V was significantly longer than that (76.8 +/- 5.5 min) of control (p < 0.01). In addition, SG extract and 11-Oxo-mog.V inhibited HUVEC-mediated LDL oxidation in a dose-dependent manner. These results demonstrate that SG extract can inhibit LDL oxidation and that 11-Oxo-mog.V, a sweet element of SG extract, provides the anti-oxidative property of SG which might reduce the atherogenic potential of LDL.
Triterpene glycosides of Siraitia grosvenori inhibit rat intestinal maltase and suppress the rise in blood glucose level after a single oral administration of maltose in rats.[Pubmed:15826043]
J Agric Food Chem. 2005 Apr 20;53(8):2941-6.
The effect of the crude extract from Siraitia grosvenori Swingle (SG-ex) on the postprandial rise in blood glucose level was investigated. The increase in plasma glucose level in response to the oral administration of maltose was significantly suppressed in rats when SG-ex was given orally 3 min before the maltose administration. There was, however, no effect when glucose was administered instead, suggesting that the antihyperglycemic effect of SG-ex is elicited by inhibition of maltase in the small intestinal epithelium. In vitro, SG-ex inhibited rat small intestinal maltase. Similar effects were also observed both in vivo and in vitro when the concentrate of the sweet elements (triterpene glycosides) prepared from SG-ex was used. Furthermore, the main sweet element of SG-ex, mogroside V, and some minor elements such as mogroside IV, Siamenoside I, and mogroside III also exhibited maltase inhibitory effect with IC50 values of 14, 12, 10, and 1.6 mM, respectively. These results suggest that SG-ex exerts anti-hyperglycemic effects in rats by inhibiting maltase activity and that these effects are at least partially exerted by its sweet elements, triterpene glycosides.
